
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis is well-positioned for future growth, with a clear focus on delivering precision and safety for patients in interventional procedures through their innovative robotic technologies, strong recurring revenue streams, and significant progress in ramping production for their MAGiC catheter. Despite a slight revenue miss in Q2, the company has received positive feedback on its MAGiC catheter and anticipates further sequential improvements in recurring revenue in H2. With key milestones expected in the form of first US sales of their GenesisX robot and Synchrony system, and a goal of reaching production of 500 MAGiC catheters per month by YE, Stereotaxis remains an attractive investment opportunity with significant upside potential.
Bears say
Stereotaxis is facing several challenges that could negatively affect its performance, including slow adoption of new technologies by healthcare providers, collaboration risk with other manufacturers and producers, long and variable sales cycles, installation and regulatory risks, and a competitive economic environment. The company has also revised its revenue guidance for 2026 to $35M, below its previous projection of $40M, due to delays in system sales. Additionally, while the recent acquisition of Robocath may provide some revenue in the short term, the company's primary focus will be on developing its next-generation system.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares